Gabrielle Wanneh

Maryland

Drug Pricing Reporter at Inside Health Policy

Mark 5:34 || Earthbender 🌿 || Drug pricing reporter @InHealthPolicy by day, vigorously watching cartoons and working on my wildest dreams by night.. 🪴🌻✨

Featured in: Favicon

insidehealthpolicy.com Favicon

msn.com

usnews.com Favicon

yahoo.com

politico.com Favicon

edweek.org Favicon

aarp.org

dcist.com

whsv.com

afro.com + 6 more

Articles

DOL Urged To Expand Biden-Era Reg To Stop Copay Assistance Exploitation

2 days ago | insidehealthpolicy.com | Gabrielle Wanneh

Advocates for patients with severe chronic conditions are calling on the Trump administration to block insurers, pharmacy benefit managers and other third-party vendors from designating certain drugs covered by CMS as “non-essential” to evade adhering to Affordable Care Act cost-sharing limits.
OPM Issues Rule Reclassifying Some Civil Servants For Potential Firings

3 days ago | insidehealthpolicy.com | Gabrielle Wanneh

The Office of Personnel Management is issuing a rule cleared by the Office of Management and Budget Friday (April 18) that will cement the creation of a new category of federal workers designed to identify members of the workforce the administration is likely to fire as it continues to sweep house of government jobs and offices it views as unnecessary or in opposition to its policymaking goals. The OPM rule would specifically set up a new “Schedule Policy/Career” category of...
Lawmakers Ask IRS To Expand HDHP Chronic Coverage Guidance

6 days ago | insidehealthpolicy.com | Gabrielle Wanneh

The House Ways & Means Committee’s Republican leaders are pressing the Internal Revenue Service to allow high-deductible health plans (HDHPs) with connected health savings accounts (HSAs) to cover the costs of additional chronic care medications and management services -- a policy in line with legislation the House passed under suspension of the rules last month but which has stalled in the Senate.
Drug Pricing EO Reveals Plan To Build Off CGT Access Model in Medicaid

1 week ago | insidehealthpolicy.com | Gabrielle Wanneh

President Donald Trump’s plans to bring down prescription drug costs include building off a Biden-era CMS innovation center model to pay for expensive sickle-cell medications based on amounts that align with the actual value of the treatments in terms of efficacy and outcomes, the president’s executive order on lowering drug prices released Tuesday (April 15) alludes.
State AGs Demand Congress Ban PBMs From Owning Pharmacies

1 week ago | insidehealthpolicy.com | Gabrielle Wanneh

Members of the National Association of Attorneys General are pressing congressional leadership to pass legislation barring pharmacy benefit managers and their parent insurance companies from owning pharmacy businesses. In a letter sent Monday (April 14), they cite the increasing influence of PBMs in the drug market due to consolidation and vertical integration as a key factor of the country’s issues with high, manipulated drug prices and the inaccessibility of medicines for patients.
Anti-Reg EO Puts Biden-Era NIH ‘Patient Access’ Plan In Crosshairs

1 week ago | insidehealthpolicy.com | Gabrielle Wanneh

New calls by the Trump administration for agencies and industry to target regulations that aren’t dictated by statute puts a controversial Biden-era accessibility plan for products developed with NIH-funded research in the crosshairs, pharmaceutical intellectual property proponents say.
CMS Seeks Stakeholder Input To Guide Medicare Deregulation Effort

1 week ago | insidehealthpolicy.com | Gabrielle Wanneh

CMS is soliciting feedback from stakeholders on ways to cut back redundant or burdensome Medicare regulations, and has specifically pegged conditions of participation, value-based purchasing, quality and safety reporting, telehealth and digital health as areas where there may be an opportunity for regulatory streamlining, in some cases because standards are already in place in industry, the states or other federal programs.
Eradication Of Generic Drug Policy Division Bodes Poorly For Access, Affordability

2 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

The elimination of an FDA division once tasked with overseeing clearances, guidance, policies and other processes affecting the regulation of generic drugs could impede access to affordable generics, Hyman, Phelps & McNamara director Kurt Karst wrote in an FDA Law Blog post Wednesday (April 9) as FDA faces mass layoffs.
Third Circuit Mulls Excessive Takings, Drug Selection Arguments In IRA Suit

2 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

Judges for the Third Circuit Court of Appeals remain skeptical that the penalties drug companies stand to face should they choose not to participate in the Medicare drug price negotiation program are akin to the government invoking a taking of a company’s patented drug products. The judges, however, had more questions to ask about certain companies’ argument that CMS acted outside of the law to select more drugs to undergo price negotiations than Congress specified in the statute.
CMS Scraps Pharmacy Notification Requirement In Final Part D Rule

2 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

The Trump administration will not require insurers or pharmacy benefit managers to notify pharmacies of their status in a pharmacy network prior to the beginning of open enrollment for a given plan year, nor will the agency allow pharmacies to walk away from plan contracts or network participation without providing justification, as these previously proposed policies were left out of the final contract year 2026 Part D rule released Friday (April 4). The move is bad news for pharmacy groups...